



**PRIOR AUTHORIZATION REQUEST FORM**  
Individual and Family Plans

**Kevzara**

**Fax back to: (833) 605-4407**

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: <input type="checkbox"/> Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	<b>Specialty/facility name (if applicable):</b>

**REQUEST FOR EXPEDITED REVIEW:** By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

**Please answer the following questions and sign.**

<p><b>Q1. Request type:</b></p> <p><input type="checkbox"/> Initial <input type="checkbox"/> Continuation</p>
<p><b>Q2. Is the medication being prescribed by or in consultation with a rheumatologist?</b></p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p><b>Q3. Does the member have a documented negative tuberculosis (TB) test (which can include a tuberculosis skin test [PPD], an interferon-release assay [IGRA], or a chest x-ray) within 6 months of initiating therapy for persons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB?</b></p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p><b>Q4. Is the requested medication being used concomitantly with any other biologic drug or targeted synthetic drug?</b></p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p><b>Q5. What is the patient's diagnosis?</b></p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**PRIOR AUTHORIZATION REQUEST FORM**  
Individual and Family Plans

**Kevzara**

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
<input type="checkbox"/> Rheumatoid arthritis (RA) - Go to 6	<input type="checkbox"/> Polymyalgia rheumatica (PMR) - Go to 10
Q6. For moderately to severely active RA, has the patient previously received or is unable to receive a biologic or targeted synthetic drug (e.g., Rinvoq, Xeljanz) indicated for moderately to severely active rheumatoid arthritis? Please attach documentation	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q7. For moderately to severely active RA, has the patient had an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to at least 15 mg/week) OR is unable to take methotrexate?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q8. For RA, has the patient tested positive for Rheumatoid factor (RF) and Anti-cyclic citrullinated peptide (anti-CCP)? Please attach documentation.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q9. Has the patient been tested for RF, Anti-CCP and C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)? Please attach documentation.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q10. For treatment of polymyalgia rheumatica (PMR), does the member meet all of the following criteria: A) 18 years of age or older; B) Documented diagnosis of polymyalgia rheumatica (PMR); C) Documented inadequate response, contraindication, or intolerance to systemic corticosteroids or steroid tapers?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q11. For continuation, has the patient achieved or maintained a positive clinical response as evidenced by disease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**PRIOR AUTHORIZATION REQUEST FORM**  
Individual and Family Plans

**Kevzara**

**Fax back to: (833) 605-4407**

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
Q12. Additional Information:	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

v2025